Beijing Baiao Pharmaceuticals Co., Ltd.

Main purpose: To use Chinese healthy subjects as the test subjects, adopt a self-crossover design, determine the plasma concentration of lidocaine in healthy subjects after administration of lidocaine gel patch licensed by Beijing Biopharma Co., Ltd., estimate the corresponding pharmacokinetic parameters, and use lidocaine gel patch (trade name: Lidoderm®, specification: 5%) licensed by Teikoku Pharma Usa Inc and produced by Teikoku Seiyaku Co., Ltd. as a reference to evaluate the bioequivalence between the preparations. Secondary objectives: 1) Evaluate the safety of the test preparation and the reference preparation in Chinese healthy subjects; 2) Evaluate the adhesion of the test preparation and the reference preparation during the medication process of Chinese healthy subjects; 3) Evaluate the skin reactivity of the test preparation and the reference preparation in Chinese healthy subjects.

Primary objective: To investigate the pharmacokinetic characteristics of the test formulation Saxagliptin Metformin Sustained-Release Tablets (I) (Specification: Each tablet contains 5 mg saxagliptin and 1000 mg metformin hydrochloride, holder: Beijing Biopharma Co., Ltd.) and the reference formulation Saxagliptin Metformin Sustained-Release Tablets (I) (trade name: Anlig®, specification: Each tablet contains 5 mg saxagliptin and 1000 mg metformin hydrochloride, licensee: AstraZeneca AB) in healthy adult Chinese subjects after a single oral administration under fasting/fed conditions, and to evaluate the bioequivalence of the two formulations when taken orally under fasting and fed conditions. Secondary objective: To evaluate the safety of the test formulation and the reference formulation in healthy adult Chinese subjects after a single oral administration under fasting/fed conditions.

To observe the relative bioavailability of a single oral dose of 80 mg (fasting/after meal) of the test preparation, Asartan Potassium Tablets (specification: 80 mg/tablet) and the reference preparation, Asartan Potassium Tablets (Edarbi®, specification: 80 mg/tablet) in healthy Chinese volunteers, analyze the pharmacokinetic parameters of the two preparations, evaluate the bioequivalence and safety of the two preparations, and provide a reference for the application and clinical use of the drug.